Vera Therapeutics Q2 net loss widens

Vera Therapeutics

05/08/2025 12:09

Overview

Vera Therapeutics Q2 net loss misses analyst expectations, EPS also missed

Co reports positive results from ORIGIN Phase 3 trial for atacicept

Vera plans BLA submission for atacicept in Q4 2025, commercial launch in 2026

Outlook

Vera plans BLA submission for atacicept in Q4 2025

Commercial launch of atacicept expected in 2026

Company to present ORIGIN 3 trial results in Q4 2025

Initial PIONEER trial results expected in Q4 2025

Result Drivers

POSITIVE TRIAL RESULTS - Vera reports positive primary endpoint results from ORIGIN Phase 3 trial, with 46% reduction in proteinuria for atacicept-treated patients

EXPANDED TRIALS - Initiated PIONEER trial to evaluate atacicept in broader IgAN and other autoimmune glomerular diseases

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
Miss
-$1.2
-$0.82 (12 Analysts)
Q2 Net Income
Miss
-$76.53 mln
-$53.20 mln (8 Analysts)
Q2 Operating Income
Miss
-$80.14 mln
-$56 mln (9 Analysts)
Q2 Operating Expenses
$80.14 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Vera Therapeutics Inc is $67.50, about 69.7% above its August 4 closing price of $20.45

Press Release: ID:nGNX3w5vvn

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)